Table 1.
Participant characteristics.
| Midazolam | Ketamine | |||
|---|---|---|---|---|
| (n = 12) | (n = 10) | test statistic | p | |
| Age in years | ||||
| mean (SD) | 35.1 (11.4) | 32.1 (10.4) | t(19) = 0.60 | 0.56 |
| [range] | [21–56] | [22–57] | ||
| Gender (n) | ||||
| Female | 10 | 8 | P = 1 | |
| Male | 2 | 2 | ||
| Race (n) | ||||
| Asian | 1 | 0 | P = 1 | |
| Arab | 0 | 1 | ||
| White | 10 | 9 | ||
| Hispanic | 1 | 0 | ||
| Education in years: | ||||
| mean (SD) | 16.3 (2.73) | 15.0 (2.74) | t(17.4) = 1.04 | 0.32 |
| [range] | [13–24] | [12–21] | ||
| Missing | 0 | 1 | ||
| Baseline comorbidities (n) | ||||
| Major Depressive Disorder | 5 | 5 | P = 0.84 | |
| Post-Traumatic Stress Disorder | 4 | 3 | P = 1.32 | |
| Anxiety disorders | 9 | 7 | P = 1.14 | |
| Mild Substance Use Disorder | 3 | 3 | P = 0.88 | |
| Bipolar Disorder | 2 | 1 | P = 1.94 | |
| Baseline symptom severity (mean (SD)) | ||||
| BSS | 7.7 (5.80) | 11.5 (7.86) | t(16.9) = 1.31 | 0.21 |
| BDI | 30.8 (13.07) | 34.9 (11.02) | t(18.9) = 1.02 | 0.32 |
| ZAN-BPD-SRV | 14.3 (7.11) | 15.4 (6.19) | t(18.9) = 0.54 | 0.6 |
| BAI | 21.8 (13.23) | 21.7 (9.15) | t(19.4) = 0.01 | 0.99 |
| SAS-SR | 4.3 (0.59) | 2.8 (0.50) | t(20) = 0.52 | 0.61 |
Anxiety disorders includes Social Anxiety Disorder, Generalized Anxiety Disorder, Panic Disorder, Obsessive-Compulsive Disorder, and Agoraphobia. Some participants had multiple comorbidities. Symptom scales included the Beck Depression Inventory (BDI), Self-report version of the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD-SRV), Beck Scale for Suicide Ideation (BSS), Beck Anxiety Inventory (BAI), and Social Adjustment Scale Self-Report (SAS-SR). For continuous variables, we compared groups with t-tests and show test statistic t and p-value. For categorical variables, we compared frequencies with Fisher’s exact tests and show odds-ratio P.